This site uses cookies

To give you the best possible experience, the GAM website uses cookies. You can read full information of our cookie use here. Your privacy is important to us and we encourage you to read our privacy policy here.

Christophe Eggmann

Christophe Eggmann is an Investment Director responsible for GAM’s Healthcare Equity strategy.

Prior to joining GAM Investments in November 2010, he was Head of Equity Research at Julius Baer and equity analyst covering the global healthcare sector. Prior to that, he held various positions as a fund manager and equity analyst at Bank Hofmann, Rothschild Bank and Credit Suisse. Christophe Eggmann holds a Master's in Business Administration and Economics from the University of Neuchâtel and is a CFA Charterholder. He is based in Zurich.

Related Articles

  • 12 July 2019

    Weekly Manager Views

    At GAM Investments’ Weekly Investment Meeting held on 10 July 2019 the speaker was Christophe Eggmann, who discussed the latest developments in healthcare.

  • 2 May 2019

    Healthcare: Ripe for disruptive innovation

    While innovation has proved a persistent theme in the healthcare industry for decades, it has not yet mirrored the bursts of disruptive innovation that characterise the technology space. GAM Investments’ Christophe Eggmann explains why he believes this is about to change abruptly and identifies some of the themes and investment opportunities that are expected to play out.

  • 25 April 2019

    GAM Talks Q2 19: Navigating current market conditions

    We asked a group of our portfolio managers a series of questions about their respective asset classes. This final video, in a series of three, asks them to discuss how they are approaching the current market environment in terms of investment themes

  • 11 April 2019

    GAM Talks Q2 19: Why should investors consider your asset class?

    We asked a group of our portfolio managers a series of questions about their respective asset classes. This first video, in a series of three, examines their current outlook and why investors should consider their asset class.

  • 2018-outlook-icon

    Tuesday, December 12, 2017

    2018 Outlook – The Merits of Active Management

    GAM’s investment experts share insights on how active management adds value in their specialist fields.

  • science_and_economists_icon

    Friday, June 02, 2017

    Biopharma Investment Cycle: Expansion Phase Still in Its Early Innings

    Unlocking the secrets of the human genome at the turn of the millennium ushered in a transformative era in drug discovery. Christophe Eggmann looks forward to the next potentially lucrative stage of the secular biopharma investment cycle.

  • 5-things-to-watch-icon

    Thursday, January 05, 2017

    2017 Outlook – Key Events

    With so much happening in parallel across political, economic and financial landscapes, it seems daunting to try to identify the one event that shaped 2016. In the following short statements, our investment experts share their predictions on which events will prove pivotal in 2017.

  • tighter_monetary_policy_icon

    Monday, December 19, 2016

    2017 Outlook – The Investment Themes to Watch

    2016 was a year of erratic markets and geopolitical shocks that sent fundamentals into the shadows. Bourses moved on speculation and surprise, challenging market participants. GAM’s investment experts put forward their key themes for the year ahead.

  • heathcare-2017-the-postelection-comeback-icon

    Thursday, December 15, 2016

    Healthcare 2017: The Postelection Comeback

    Given an environment conducive to merger and acquisition (M&A) activity, Christophe Eggman, investment director for healthcare equities, looks ahead to 2017 and beyond with a sense of optimism.

  • biopharma_icon

    Tuesday, July 12, 2016

    Pharma: Healthy Returns Ahead

    After a challenging nine months, healthcare investors can look forward to a turnaround in the sector’s fortunes. Christophe Eggmann, investment director for healthcare equities, explains why the sector is set up for a successful second half with plenty of opportunities in biopharma.

Scroll to top